Elevated levels of serum adenosine deaminase in type 2 diabetes mellitus patients

Authors

  • Venkata Bharatkumar Pinnelli Associate Professor, Department of Biochemistry, Vydehi Institute of Medical Sciences and Research Centre, EPIP Area, Nallurhalli, Whitefield, Bangalore
  • Jayashankar C. A. Associate Professor, Department of Medicine, Vydehi Institute of Medical Sciences and Research Centre, EPIP Area, Nallurhalli, Whitefield, Bangalore
  • Shrabani Mohanty Professor, Department of Biochemistry, Vydehi Institute of Medical Sciences and Research Centre, EPIP Area, Nallurhalli, Whitefield, Bangalore
  • Asha G. Assistant Professor, Department of Biochemistry, Vydehi Institute of Medical Sciences and Research Centre, EPIP Area, Nallurhalli, Whitefield, Bangalore
  • Minu Mary Mathai Assistant Professor, Department of Biochemistry, Vydehi Institute of Medical Sciences and Research Centre, EPIP Area, Nallurhalli, Whitefield, Bangalore
  • Raghavendra D.S. Professor and Head, Department of Biochemistry, Vydehi Institute of Medical Sciences and Research Centre, EPIP Area, Nallurhalli, Whitefield, Bangalore

DOI:

https://doi.org/10.18203/2320-6012.ijrms20160018

Keywords:

Adenosine deaminase, Type 2 Diabetes Mellitus, Hyperglycaemia, Insulin resistance

Abstract

Background: Diabetes Mellitus (DM) is a metabolic disorder characterized by an absolute or relative deficiency of insulin and insulin resistance or both. Adenosine deaminase (ADA) is an enzyme, that catalyses the irreversible hydrolytic deamination of adenosine to uric acid. Since ADA activity is associated with T-lymphocyte activity and insulin resistance, in the present study, we measured serum ADA activity in type 2 Diabetes mellitus (T2DM) patients to evaluate the relationship between serum ADA activities with glycemic status.

Methods: A total of 100 T2DM patients and controls were recruited for the study. Estimation of fasting plasma glucose (FPG), postprandial plasma glucose (PPG), HbA1c and fasting lipid profile was done. Serum ADA level was estimated by Colorimetric method. Statistical analysis of data was performed using the SPSS version 15.

Results: ADA level was significantly higher (p<0.001) in patients with T2DM (45.5+4.6 U/L) than controls. A significant positive correlation was observed between serum ADA and HbA1c (r=0.585), FPG (r=0.495), PPG (0.387) and serum triglycerides (r=0.375) among subjects with T2DM but not among non-diabetic controls.

Conclusions: In the present study, serum ADA activity in T2DM patients has been increased. High ADA activity reduces the glucose uptake into cells; therefore, insulin resistance is related to ADA activity.

References

IDF. Diabetes atlas. Brussels, Belgium: International Diabetes Federation. 2013;4.

Reddy KS, Shah B, Varghese C, Ramadoss A. Chronic diseases 3. Lancet 2005;366:1746-51.

Unwin N, Whiting D, Guariguata L, Ghyoot G, Gan D, editors. 5th ed. Brussels: International Diabetes Federation. International Diabetes Federation, Diabetes Atlas. 2011:11-74.

Anjana RM, Pradeepa R, Deepa M, Datta M, Sudha V, Unnikrishnan R, et al. Prevalence of diabetes and prediabetes (impaired fasting glucose and/or impaired glucose tolerance) in urban and rural India: Phase I results of the Indian Council of Medical research-India Diabetes (ICMR-INDIAB) study. Diabetologia. 2011;54:3022-7.

Spencer N, Hopkinson DA, Harris H. Adenosine deaminase polymorphism in man. Annals of Human Genetics. 1968;32(1):9-14.

Lee JG, Kang DG, Yu JR, Kim Y, Kim J, Koh G, et al. Changes in adenosine deaminase activity in patients with type 2 diabetes mellitus and effect of DPP-4 inhibitor treatment on ADA activity. Diabetes and Metabolism Journal. 2011;35(2):149-58.

Van der Weyden MB, Kelley WN. Human adenosine deaminase. Distribution and properties. The Journal of Biological Chemistry. 1976;251(18):5448-56.

Hoshino T, Yamada K, Masuoda K, Tsuboi L, Itoh K, Nonaka K. Elevated adenosine deaminase activity in the serum of patients with Diabetes Mellitus. Diabetes Res Clin Prac. 1994;25:97-102.

Shiva Prakash M, Chennaiah S, Murthy YSR. Altered Adenosine Deaminase activity in type 2 Diabetes Mellitus. JICAM. 2006;7:114-7.

Wang JL, Yuan SY, Shao JF. Determination of serum adenosine deaminase : its diagnostic value in jaundice and liver fibrosis. Zhonghua Nei ke Za Zhi. 1986;25(2):79-81.

Yu C, Chen Y, Cline GW, Zhang D, Zong H, Wang Y, et al. Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. The Journal of Biological Chemistry. 2002;277(52):50230-6.

Ramani NSC, Murthy KN, Prasad RBN. Role of Adenosine Deaminase to predict glycemic status in type -2 Diabetes mellitus. J clin Bio med Sci. 2012;2:123-32.

Reddy MA, Rao YN, Singh Y, Saxsena A. Adenosine Deaminase and protein Tyrosine Phosphatase activities in liver and peritoneal macrophages of streptozocin induced diabetic mice. Indian Journal of Clinical Biochemistry. 1995;10(2):66-71.

Warrier AC, Rao NY, Mishra TK, Kulpati DS, Mishra KT, Kabi BC. Evaluation of Adenosine Deaminase activity and lipid peroxidation levels in Diabetes Mellitus. Indian Journal of Clinical Biochemistry. 1995;10(1):9-13.

Erbagci AB, Araz M, Koyluoglu Y, Ozdemir Y, Tarakcyoolu M. Elevated Adenosine Deaminase Activity is not implicated in microvascular complications of type 2 Diabetes Mellitus Except HbA1c. Turkish Journal of Endocrinology and Metabolism. 2000;4(3):95-9.

Jeppsson J, Kobold U, Finke JBA, Hoelzel W, Tadao H, Kor M, et al. Approved IFCC Reference Method for the measurement of HbA1c in Human Blood.m Clin. Chem. Lab Med. 2002;40(1):78-89.

Giusti G. Adenosine deaminase. In :H.U. Bergmeyer (ed), Methods of enzymatic analysis, Verlag chemie, Weinheim and Academic Press, 2nd edition. New York. 1974:1092-9.

Gitangali G, Neerja. The effect of Hyperglycemia on some Biochemical parameters in Diabetes Mellitus. JCDR. 2010;4:3181-6.

Erkilic K, Evereklioglu C, Cekmen M. Adenosine deaminase enzyme activity is increased and negatively correlates with catalase, SOD, and GSH in patients Behcet’s Disease. Original contributions/ clinical and laboratory investigations. Mediators Infamm. 2003;12:107-16.

Poliani PL, Vermi W, Facchetti F. Thymus microenvironment in human primary immunodeficiency diseases. Current Opinion in Allergy and Clinical Immunology. 2009;9(6):489-95.

Sauer AV, Brigida I, Carriglio N, Aiuti A. Autoimmune dysregulation and purine metabolism in adenosine deaminase deficiency. Frontiers in Immunology. 2012;3.

Apasov SG, Blackburn MR, Kellems RE, Smith PT, Sitkovsky MV. Adenosine deaminase deficiency increases thymic apoptosis and causes defective T cell receptor signalling. The Journal of Clinical Investigation. 2001;108(1):131-41.

Kurtul N, Pence S, Akarsu E, Kocoglu H, Aksoy Y, Aksoy H. Adenosine deaminase activity in the serum of type 2 diabetic patients. Acta Medica. 2004;47(1):33-5.

Prakash MS, Chennaiah S, Murthy YSR, Anjaiah E, Rao SA, Suresh C. Altered adenosine deaminase activity in type 2 diabetes mellitus. Indian Academy of Clinical Medicine. 2006;7(2):114-7.

Kaur A, Kukreja S, Malhotra N, Neha. Serum Adenosine Deaminase Activity and Its Correlation with Glycated Haemoglobin Levels in Patients of Type 2 Diabetes Mellitus. Journal of Clinical and Diagnostic Research. 2012;6(2):252-6.

Downloads

Published

2016-12-24

How to Cite

Pinnelli, V. B., C. A., J., Mohanty, S., G., A., Mathai, M. M., & D.S., R. (2016). Elevated levels of serum adenosine deaminase in type 2 diabetes mellitus patients. International Journal of Research in Medical Sciences, 4(1), 131–134. https://doi.org/10.18203/2320-6012.ijrms20160018

Issue

Vol. 4 No. 1 (2016): January 2016

Section

Original Research Articles